Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development...

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug
Development Conference

NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical
stage biopharmaceutical company and a leading developer of oncology compounds
directed to cancer stem cell targets, today announced that the Company's CEO,
Ivan Bergstein M.D. has been invited to present at the New Frontiers in Cancer
Drug Development conference which is part of IBC's Drug Discovery and
Development Week in Boston, MA. Dr. Bergstein's presentation, entitled
"Developing Drug Candidates Directed to Cancer Stem Cell Targets: Preclinical
and Clinical Update" is scheduled for 9:50AM on Wednesday August 5(th) at the
World Trade Center/Seaport Hotel in Boston. Dr. Bergstein has also been
invited to participate in a panel discussion following the presentations.

Cancer stem cell targeted therapeutics have emerged as the next frontier in
the fight against cancer. As such, this field is significantly influencing
current decision making with respect to oncology drug development. With this
in mind, Dr. Bergstein's presentation will cover novel pre-clinical and
clinical development paradigms, including human trial design, of drug
candidates that target cancer stem cells. The talk will also feature
Stemline's latest clinical data, as well as results from its pre-clinical
pipeline and drug discovery platforms.

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company
developing novel oncology compounds directed to cancer stem cell targets.
Stemline's lead compound, SL-401, targets the interleukin-3 receptor present
on multiple hematological cancers including leukemia blasts and leukemia
cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at
tolerable doses in a multi-center Phase I human clinical trial. Stemline is
also developing a portfolio of biological and small molecule compounds
directed at multiple high value cancer stem cell targets of a variety of
hematological and solid cancers. Stemline has built a robust discovery
platform called "StemScreen(R)" which the Company has utilized to identify
multiple compounds that target and impair cancer stem cells. For more
information, please visit the Company's website at www.stemline.com.
Stemline Contact: Tom Cirrito, PhD, Director of Operations, Stemline
Therapeutics, Inc. Tel: 212-531-5976; Email: tcirrito@stemline.com

SOURCE Stemline Therapeutics, Inc.

Tom Cirrito, PhD, Director of Operations of Stemline Therapeutics, Inc.
+1-212-531-5976, tcirrito@stemline.com